Korean J Dermatol.  2021 Mar;59(3):196-205.

Effectiveness and Safety of Two Different Formulations of Oral Propranolol Treatment for 375 Cases of Infantile Hemangioma: A Korean Single-center Experience

Affiliations
  • 1Departments of Dermatology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea
  • 2Departments of Plastic and Reconstructive Surgery , School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea
  • 3Departments of Radiology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea
  • 4Departments of Surgery , School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea
  • 5Departments of Pediatrics , School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea

Abstract

Background
Oral propranolol has recently been introduced as a successful treatment for infantile hemangioma (IH). Though, there are limited reports on this treatment including large number of Korean patients with IH covering a long-term powder and solution formulation period.
Objective
We investigated the effectiveness and side effects of two different formulations of oral propranolol treatment in patients with IH at a Korean tertiary university hospital.
Methods
From June 2011 to October 2019, 375 patients were treated with powder- or solution-type oral propranolol starting at 1 mg/kg/day and increasing up to 3 mg/kg/day. Drug effectiveness was evaluated on four scales through sequential photographs by two dermatologists. Side effects were recorded on a medical chart.
Results
Overall, the mean improvement scale was 2.61±0.73 at 3 months after treatment initiation. The scale was higher for solution-type than for powder-type oral propranolol at the 3-month follow-up (2.71±0.79 vs. 2.54±0.67, p<0.05). The patients’ mean duration of treatment was 8.56±5.85 months, which was shorter for solution-type than for powder-type oral propranolol (6.0 vs. 10.69 months, p<0.05). Among the total number of patients, 22 reported mild side effects, including loose stools and noticeable sleep disturbance, and few serious side effects such as grunting, while two patients required medical intervention.
Conclusion
The patients in our study were effectively treated for IH with oral propranolol without significant side effects and had a shorter treatment duration with solution-type oral propranolol than with powder-type oral propranolol.

Keyword

Formulation; Infantile hemangioma; Propranolol
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr